Search - tctmd.com

Displaying 41 - 60 of 84

Sort: Relevancy | Date

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News SCAI 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

L.A. McKeown

May 15, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Shelley Wood

May 05, 2017

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Shelley Wood

May 03, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News TCT 2016

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Todd Neale

October 30, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

Michael O'Riordan

August 01, 2016

News Daily News

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

Michael O'Riordan

August 01, 2016

News Daily News

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Todd Neale

July 06, 2016

Advertisement

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Bioresorbable Scaffolds: Where Do We Go From Here?

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

The Bioresorbable Stent Story So Far: What Promise? What Price?

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content